We're thrilled to have been named one of Boston Business Journal's 2025 Best Places to Work — the BBJ’s exclusive ranking of the Massachusetts companies that have built outstanding work environments for their people! .#BBJ #BPTW #BPTW2025 #BiotechNews #Biotech #mRNAResearch #mRNA

RT @BiotechTV: 𝐀𝐒𝐂𝐎 𝟐𝟎𝟐𝟓: @StrandTx's Co-Founder & CEO @DrSynbio discusses the clinical data presentation for the company's IL-12, self-re….

Excited to share preliminary FIH Phase 1 data for STX-001: early signs of monotherapy activity and favorable safety in advanced solid tumors. Join us at ASCO: June 1, 9:00 AM-12:00 PM CDT, Abstract Number: 9556, Location: Hall A. Read our press release:

Come by our abstract presentation tomorrow at #ASGCT2025 to learn about the groundbreaking data from the preclinical program for STX-003. Session Title: Targeted Gene and Cell Therapy for Cancer.Date and Time: May 17, 8:15-8:30 am CT.Abstract Number: 394.Location: Room 291-292

Come by our poster presentation today at #ASGCT2025 to learn about exciting ongoing work for our STX-005 program!.Session Details:.Date and Time: May 13, 6:00-7:30 pm CT.Abstract #781.Location: Hall I1-I2.

Over the weekend, Strands had the opportunity to volunteer at the #MassScienceFair Middle School State Fair! Shoutout to Gautam, Danish, Sanjana, Eloise, and Jaspreet for getting involved. #BeCurious #BiotechNews #Biotech #mRNAResearch #mRNA #mRNATherapies

Wishing all of the moms of Strand a happy Mother's Day! 💐 #MothersDay #BiotechNews #Biotech #mRNAResearch #mRNA #mRNATherapies

Strand had the wonderful opportunity to host some fantastic students from MIT's BioCEL and Ron Weiss's lab. It was fun to answer questions about life sciences careers, mRNA, biotech, and more! 🔬🧬 #BiotechNews #Biotech #mRNAResearch #mRNA #mRNATherapies

ASGCT Session Details:.Session Type: Oral.Session Title: Targeted Gene and Cell Therapy for Cancer.Date and Time: May 17, 8:15-8:30 am CT.Abstract Number: 394.Location: Room 291-292.Full abstract is available on the ASGCT Annual Meeting website.

Full abstract is available on the AACR Annual Meeting website.

AACR Session Details:.Session Type: Poster.Session Title: PO.IM01.12 Local Treatments, Novel Tools, and Delivery Systems to Manipulate Tumor Immunity.Date and Time: April 28, 2:00-5:00 pm CT.Abstract Number: 3472/11.Location: Section 37.

Our data demonstrate that Strand’s programmable mRNA genetic circuits can target the expression of interleukin-12 (IL-12) to cancerous tissue to help achieve the right therapeutic dose while reducing off target side effects. Read our press release:

Join us at these sessions to learn more about the groundbreaking potential of STX-003, a systemically delivered programmable mRNA therapy to treat solid tumors.

Strand Therapeutics looks forward to the upcoming presentations of its STX-003 preclinical data at the 2025 annual meetings of the American Association for Cancer Research (AACR) and the American Society of Gene and Cell Therapy (ASGCT).

Come by our poster today at #AACR25 to learn about the groundbreaking data from the preclinical program for STX-003 - a systemically delivered self-replicating mRNA encoding IL-12. Session Details:.Date and Time: April 28, 2:00-5:00 pm CT.Location: Section 37.

Last week, Strands volunteered at Women's Lunch Place! They cooked and served hot meals to help women experiencing homelessness and poverty. Thanks for having us, @WLPBoston! #BiotechNews #Biotech #mRNAResearch #mRNA #mRNATherapies

Tomorrow is International Women's Day! Our team onsite is wearing purple and celebrating women's accomplishments today (and every day).💜#BioTech #InternationalWomensDay #IWD2025

Happy Halloween from all of us at Strand! 🎃#Halloween #BiotechNews #Biotech #mRNAResearch #mRNA #mRNATherapies

Strand had the wonderful opportunity to host some fantastic students from the Princeton Biotech Group during their Boston trip. It was fun to answer questions about mRNA, biotech, being in the clinic, and more!

RT @benchling: How do you precisely control the timing and location of therapeutic protein expression? @StrandTx develops first-in-class pr….